Latest Conference Articles

ACC.21: High- and Low-Dose Aspirin Both Effective for Patients with Established Cardiovascular Disease

ACC.21: High- and Low-Dose Aspirin Both Effective for Patients with Established Cardiovascular Disease

May 21st 2021

ACC

ACC.21: There was no difference found between high- and low-dose aspirin in terms of effectiveness and safety in patients with established CVD, according to new research.

ACC.21: Survival After MI Far Worse for Black Patients from Disadvantaged Neighborhoods

ACC.21: Survival After MI Far Worse for Black Patients from Disadvantaged Neighborhoods

May 14th 2021

ACC

ACC.21: Black patients from disadvantaged neighborhoods were found almost 20% more likely to die within 5 years of MI than white patients from well-resourced ones in a new study.

ATS 2021: Tezepelumab Reduces Exacerbations in Oral Corticosteroid-dependent Patients with Severe Asthma

ATS 2021: Tezepelumab Reduces Exacerbations in Oral Corticosteroid-dependent Patients with Severe Asthma

May 13th 2021

ATS

ATS 2021: In a subgroup of oral corticosteroid-dependent patients with severe asthma from the newly released NAVIGATOR study, tezepelumab reduced exacerbations and improved lung function.

ATS.2021: Study Finds Odds of Uncontrolled Asthma Increase with Higher Pandemic-related Stress

ATS.2021: Study Finds Odds of Uncontrolled Asthma Increase with Higher Pandemic-related Stress

May 13th 2021

ATS

ATS.2021: Odds of uncontrolled asthma in response to pandemic-related stress increased in a significant dose-response manner among adult respondents to a new survey.

ACC.21: Prediabetes Significantly Increases Risk for MACE, According to New Findings

ACC.21: Prediabetes Significantly Increases Risk for MACE, According to New Findings

May 13th 2021

ACC

ACC.21: Findings from a study released in advance of the ACC annual meeting suggest that prediabetes confers nearly twice the risk of major cardiovascular events vs normoglycemia.

ATS.2021: At-risk Asthma Phenotypes Defined Using 4 Simple Metrics

ATS.2021: At-risk Asthma Phenotypes Defined Using 4 Simple Metrics

May 12th 2021

ATS

ATS.2021. Study authors categorized asthma patients using age at onset, T2 biomarkers, and IL-6 levels, creating 12 phenotypes for additional study.

ATS 2021: Severe COPD Exacerbations May be Associated with Increased Mortality Risk

ATS 2021: Severe COPD Exacerbations May be Associated with Increased Mortality Risk

May 12th 2021

ATS

ATS 2021: The risk of morbidity and death in patients with COPD increases among those with moderate exacerbation, and even more so for severe exacerbation, new research suggests.

ATS 2021: Researchers Project Burden of COPD Will be Worse in 2050, Especially in US

ATS 2021: Researchers Project Burden of COPD Will be Worse in 2050, Especially in US

May 11th 2021

ATS

In an abstract being presenting at the upcoming ATS 2021 International Conference, researchers estimate that by 2050 the US will lead the Americas in prevalence of COPD.

Black Women at Risk Early in Life for Future Cardiovascular Disease

Black Women at Risk Early in Life for Future Cardiovascular Disease

May 11th 2021

ACC

ACC.21: High rates of obesity, hypertension, and hyperlipidemia found in Black women in their 20s and 30s are of significant concern, says the author of a study to be presented at the ACC meeting.

ATS 2021: Triple Combination Therapy May Benefit “Wide Spectrum” of Patients with COPD

ATS 2021: Triple Combination Therapy May Benefit “Wide Spectrum” of Patients with COPD

May 11th 2021

ATS

American Thoracic Society 2021 International Conference: In a subset of patients from the ETHOS study, triple combination therapy was found beneficial for those with moderate COPD.